Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema

Mashhad University of Medical Sciences1 个研究点分布在 1 个国家开始时间: 2009年5月最近更新: 2010年10月8日

适应症

干预措施

试验速览

阶段: 不适用
状态: 终止
发起方: Mashhad University of Medical Sciences
试验地点: 1

研究概览研究设计入排标准研究组 & 干预措施研究者研究点记录与标识符相似试验

研究概览

简要总结

Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).

研究设计

研究类型: Interventional
主要目的: Treatment
盲法: Single (Investigator)

入排标准

性别: All
接受健康志愿者: 否

入选标准

•type 2 diabetes
•Non proliferative diabetic retinopathy(NPDR) stage of diabetic retinopathy
•patients with refractory DME CSME (patients with the last MPC at least 3 months before and no improvement was observed in BCVA, macular thickness inOCT, clinical examination and fundus photographs of patients )
•Absence of PVD in the B-scan
•Absence of PVD in OCT of macular area and optic disk
•Absence of PVD in slit lamp biomicroscopy(SLE)
•the last PRP session was at least 3 months ago.
•Absence of traction on macula in clinical examination and OCT

排除标准

•One eye patients
•Patients who are candidates for intraocular surgery.
•Patients with the history of glaucoma or ocular hypertension
•Patients with a history of vitrectomy in the study eye
•Not being able to refer for the next visits
•Eyes with cataract that makes the assessment of the macula impossible.
•Intraretinal hemorrhage at fovea that will interfere with OCT.

研究组 & 干预措施

TPA,IVB,F/U

Experimental

干预措施: Tissue Plasminogen Activator,bevacizumab ,follow up (Drug)

研究者

发起方

Mashhad University of Medical Sciences

申办方类型

Other

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

1 期

A clinical trial of a clot dissolving drug and gas, injected into the eye, to treat bleeding associated with wet age-related macular degeneratioSub-macular haemorrhage secondary to wet macular degenerationMedDRA version: 16.0Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 16.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disorders

EUCTR2012-004078-24-GBKing's College London

已完成

不适用

Effect of intraocular plasmin injection, in diabetic macular edemaDiabetes mellitus.Background retinopathy and retinal vascular changes

IRCT2015050522112N1Vice Chancellor for research of Zahedan University of Medical Science20

已完成

不适用

Intravitreal versus submacular injection of rtPA for acute submacular haemorrhages.Acute submacular haemorrhages.

NL-OMON25583The Rotterdam Eye HospitalPO Box 70030 3000 LM Rotterdam24

已完成

2 期

Intravitreal injection of methotrexate in persistent diabetic macular edemaResistant macular edema in diabetic patients.Distrubtion of retinal layers due to edema

IRCT201610098983N2Guilan University of Medical Sciences,Vice chancellor for research42

已完成

3 期

The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edemadiabetic macular edema

JPRN-UMIN000017037Jichi Medica University, Saitama Medical Center100